Trial Profile

A Phase 2 Study of INCB57643 (BET Inhibitor) in Combination With Ruxolitinib in JAK Inhibitor-naïve Patients With Myelofibrosis

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 057643 (Primary) ; Ruxolitinib (Primary)
Indications Myelofibrosis
Focus Adverse reactions; Proof of concept

Most Recent Events

18 May 2025 Status changed from not yet recruiting to withdrawn prior to enrolment because no participants were accrued.
29 Oct 2024 According to an Incyte Corporation media release, additional data from this trial is anticipated in the fourth quarter of 2024.
30 Sep 2024 Status changed from planning to not yet recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com